PharmaEngine (ROCO:4162) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4162 PharmaEngine Inc ROCO:4162
83 GF Score
Price NT$61.50
GF Value NT$107.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PharmaEngine Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:4162
83GF Score
PharmaEngine Inc ROCO:4162
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$61.50 is trading 43% below its estimated GF Value™ of NT$107.92. GuruFocus considers PharmaEngine to be Possible Value Trap.

Key valuation signals for ROCO:4162:

  • Dividends Received:
  • GF Value™: NT$107.92 vs. price of NT$61.50 (43% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
83GF Score

Get the complete analysis for ROCO:4162

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.50
Price
NT$107.92
GF Value